Compositions and Methods of Treating Muscular Dystrophy with Thromboxane-A2 Receptor Antagonists
The present invention is directed to methods of treating and/or ameliorating muscular dystrophy and/or treating cardiomyopathy in muscular dystrophy patients by administration of a therapeutically effective amount of a thromboxane A 2 receptor antagonist.
1 . A method of treating or ameliorating muscular dystrophy in a subject in need of treatment thereof, comprising administering a therapeutically effective amount of a thromboxane A 2 receptor antagonist to the patient.
2 . The method of claim 1 , wherein the muscular dystrophy is fibrosis is selected from the group consisting of Duchenne MD (DMD), Becker MD, and Limb-Girdle MD.
3 . The method of claim 1 , further comprising administering the thromboxane A 2 antagonist to the patient on a chronic basis.
4 . The method of claim 3 , wherein the cardiac function of the patient is maintained or improved.
5 . The method of claim 3 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), and pharmaceutically acceptable salts thereof.
6 . The method of claim 3 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium).
7 . The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered orally, intranasally, rectally, vaginally, sublingually, buccally, parenterally, or transdermally.
8 . The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered parenterally.
9 . The method of claim 1 , wherein the thromboxane A 2 receptor antagonist is administered orally.
10 . The method of claim 3 , wherein the thromboxane A 2 receptor antagonist is administered prophylactically to prevent cardiomyopathy in the patient.
11 . The method of claim 3 , wherein the thromboxane A 2 receptor antagonist is administered prophylactically to prevent gastrointestinal dysfunction in the patient.
12 . The method of claim 3 , wherein the therapeutically effective amount is from about 50 mg to about 500 mg.
13 . The method of claim 5 , wherein the therapeutically effective amount is from about 150 mg to about 350 mg per day and the ifetroban is administered orally.
14 . A method of treating cardiac and/or gastrointestinal dysfunction in a human patient suffering from muscular dystrophy, comprising chronically administering a therapeutically effective amount of a thromboxane A 2 receptor antagonist to the human patient.
15 . The method of claim 14 , wherein the therapeutically effective amount is from about 100 mg to about 500 mg.
16 . The method of claim 14 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), and pharmaceutically acceptable salts thereof.
17 . The method of claim 16 , wherein the thromboxane A 2 receptor antagonist is [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid, monosodium salt (Ifetroban Sodium).
18 . The method of claim 16 , wherein the therapeutically effective amount is from about, 150 mg to about 350 mg per day and the ifetroban is administered orally.
19 . The method of claim 13 , wherein the gastrointestinal dysfunction is smooth muscle dysfunction.
20 . The method of claim 16 , wherein the therapeutically effective amount of ifetroban provides improved ventricular function to the heart of the patient.